Results 71 to 80 of about 576 (123)
Ethical Considerations Regarding Psychedelics for Clinical Pain Research. [PDF]
Robinson CL +7 more
europepmc +1 more source
Licit use of illicit drugs for treating depression: the pill and the process. [PDF]
Torrado Pacheco A, Moghaddam B.
europepmc +1 more source
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism. [PDF]
Mitchell JM, Anderson BT.
europepmc +1 more source
Cabergoline as a preventive migraine treatment: A randomized clinical pilot trial. [PDF]
Hjelholt AJ +5 more
europepmc +1 more source
Psychedelics: Safety and Efficacy. [PDF]
Miller N.
europepmc +1 more source
Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins. [PDF]
Rouaud A, Calder AE, Hasler G.
europepmc +1 more source
SYNTHESIS OF ERGOLINE DERIVATIVES; ESTERIFICATION OF LYSERGOL
openaire +1 more source
Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money. [PDF]
Humphreys K +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Serotonergic ergoline derivatives
Bioorganic & Medicinal Chemistry Letters, 1998Novel classes of 13- and 14-tertbutyl-ergoline derivatives were prepared, and characterised in vitro for their affinity for adrenergic, dopaminergic and serotonergic binding sites. This study particularly examines the importance of the presence and the position of the tert-butyl group in conferring either significant 5-HT1A or 5-HT2 affinity and ...
S, Mantegani +6 more
openaire +2 more sources

